Evaluation of quality and efficacy consistency of generic drugs of TUL Biapenem for injection

Recently, Biapenem for injection (specification: 0.3g) declared by Zhuhai United Laboratories Co., Ltd. was approved by the State Drug Administration and passed the quality and efficacy consistency evaluation of generic drugs (acceptance number: CYHB2150546).

Biapenem for injection is a new type of carbapenem antibiotic with a wide antibacterial spectrum and good antibacterial activity β- The stability of lactam enzyme. Clinically suitable for the treatment of sepsis, pneumonia, acute bronchitis, etc. caused by sensitive bacteria. Compared to other carbapenem varieties, Biapenem has characteristics such as less nephrotoxicity and no central nervous system toxicity. At present, Biapenem is a Class B drug in the National Medical Insurance Catalogue (2021 Edition).

This approval will further help TUL consolidate its dominant position in the field of anti infection. TUL will continue to be committed to the research and development of new products and the promotion of consistency evaluation, so as to provide more safe and efficient drug choices for patients.